切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2013, Vol. 07 ›› Issue (05) : 355 -359. doi: 10.3877/cma.j.issn.1674-0807.2013.05.009

综述

微小RNA 29 在乳腺癌中的研究进展
范旭龙1, 吴爱国1,()   
  1. 1.510280 广州,南方医科大学珠江医院普通外科
  • 收稿日期:2013-07-19 出版日期:2013-10-01
  • 通信作者: 吴爱国

Research progress on microRNA 29 in breast cancer

Xu-long FAN, Ai-guo WU()   

  • Received:2013-07-19 Published:2013-10-01
  • Corresponding author: Ai-guo WU
引用本文:

范旭龙, 吴爱国. 微小RNA 29 在乳腺癌中的研究进展[J/OL]. 中华乳腺病杂志(电子版), 2013, 07(05): 355-359.

Xu-long FAN, Ai-guo WU. Research progress on microRNA 29 in breast cancer[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2013, 07(05): 355-359.

图1 miR-29 的调控机制 miR-29 通过调控其靶基因的表达实现对乳腺癌侵袭、肿瘤干细胞调控、凋亡和表观遗传学等方面的调控
[1]
Lagos-Quintana M,Rauhut R,Lendeckel W,et al.Identification of novel genes coding for small expressed RNAs[J].Science,2001,294(5543):853-858.
[2]
Kriegel AJ, Liu Y, Fang Y, et al.The miR-29 family:genomics, cell biology,and relevance to renal and cardiovascular injury[J].Physiol Genomics,2012,44(4):237-244.
[3]
Luna C, Li G, Qiu J, et al.Cross-talk between miR-29 and transforming growth factor-betas in trabecular meshwork cells[J].Invest Ophthalmol Vis Sci,2011,52(6):3567-3572.
[4]
Wang H, Garzon R, Sun H, et al.NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma[J].Cancer Cell,2008,14(5):369-381.
[5]
Van der Auwera I, Limame R, van Dam P, et al.Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype[J].Br J Cancer,2010,103(4):532-541.
[6]
Iorio MV, Ferracin M, Liu CG, et al.MicroRNA gene expression deregulation in human breast cancer[J].Cancer Res,2005,65(16):7065-7070.
[7]
Wang C,Bian Z,Wei D,et al.miR-29b regulates migration of human breast cancer cells[J].Mol Cell Biochem,2011,352(1-2):197-207.
[8]
Gebeshuber CA, Zatloukal K, Martinez J.miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis[J].EMBO Rep,2009,10(4):400-405.
[9]
Cittelly DM, Finlay-Schultz J, Howe EN, et al.Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4[J].Oncogene,2012,32(20):2555-2564.
[10]
Buffa FM, Camps C, Winchester L, et al.microRNAassociated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer[J].Cancer Res, 2011,71(17):5635-5645.
[11]
White NM, Fatoohi E, Metias M, et al.Metastamirs: a stepping stone towards improved cancer management[J].Nat Rev Clin Oncol,2011,8(2):75-84.
[12]
Cochrane DR, Jacobsen BM, Connaghan KD, et al.Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer[J].Mol Cell Endocrinol,2012,355(1):15-24.
[13]
Al-Ahmadi W,Al-Ghamdi M,Al-Souhibani N,et al.miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer[J].J Pathol,2013,230(1):28-38.
[14]
Wang C, Gao C, Zhuang JL, et al.A combined approach identifies three mRNAs that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7[J].J Cancer Res Clin Oncol,2012,138(12):2127-2136.
[15]
Fang JH, Zhou HC, Zeng C, et al.MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression[J].Hepatology, 2011,54(5):1729-1740.
[16]
Chou J, Lin JH, Brenot A, et al.GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression[J].Nat Cell Biol,2013,15(2):201-213.
[17]
Gerson KD, Shearstone JR, Maddula VS, et al.Integrin beta4 regulates SPARC protein to promote invasion[J].J Biol Chem,2012,287(13):9835-9844.
[18]
Li H, Solomon E, Duhachek Muggy S, et al.Metalloproteasedisintegrin ADAM12 expression is regulated by Notch signaling via microRNA-29[J].J Biol Chem,2011,286(24):21500-21510.
[19]
Xiong Y, Fang JH, Yun JP, et al.Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma[J].Hepatology,2010,51(3):836-845.
[20]
Park SY, Lee JH, Ha M, et al.miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42[J].Nat Struct Mol Biol,2009,16(1):23-29.
[21]
Suzuki HI, Yamagata K, Sugimoto K, et al.Modulation of microRNA processing by p53[J].Nature, 2009,460(7254):529-533.
[22]
Fabbri M, Garzon R, Cimmino A, et al.MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B[J].Proc Natl Acad Sci U S A,2007,104(40):15805-15810.
[23]
Nguyen T, Kuo C, Nicholl MB, et al.Downregulation of microRNA-29c is associated with hypermethylation of tumorrelated genes and disease outcome in cutaneous melanoma[J].Epigenetics,2011,6(3):388-394.
[24]
Braconi C, Kogure T, Valeri N, et al.microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer[J].Oncogene, 2011, 30(47):4750-4756.
[25]
Kojima K, Takata A,Vadnais C,et al.MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma[J].Nat Commun,2011,2:338.
[26]
Ehrlich M.DNA methylation in cancer: too much, but also too little[J].Oncogene,2002,21(35):5400-5413.
[27]
Liu WR, Shi YH, Peng YF, et al.Epigenetics of hepatocellular carcinoma: a new horizon[J].Chin Med J(Engl),2012,125(13):2349-2360.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[5] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[6] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[7] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[8] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[9] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[10] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[14] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[15] 王国强, 张纲, 唐建坡, 张玉国, 杨永江. LINC00839 调节miR-17-5p/WEE1 轴对结直肠癌细胞增殖、凋亡和迁移的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 491-499.
阅读次数
全文


摘要